OWC Pharmaceutical Research(DE:0OW)
DE:0OW
OWC Pharmaceutical Research financials statements
OWC Pharmaceutical Research (0OW) Ratios
0 Followers
OWC Pharmaceutical Research Ratios
DE:0OW's free cash flow for Q3 2019 was $-372.00K. For the 2019 fiscal year, DE:0OW's free cash flow was increased by $0.00 and operating cash flow was $-372.00K. See a summary of the company’s cash flow.
| Ratios | Dec 18 | Dec 17 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 8.03 | 3.86 |
| Quick Ratio | 8.03 | 3.86 |
| Cash Ratio | 7.91 | 3.59 |
| Solvency Ratio | -0.79 | -16.82 |
| Operating Cash Flow Ratio | -5.71 | -4.38 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ -9.48M | $ 774.36K |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.38 | 1.34 |
| Debt Service Coverage Ratio | -1189.00 | 0.00 |
| Interest Coverage Ratio | -1432.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.97 | 0.21 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 238.78% | 100.10% |
| Return on Assets (ROA) | -288.71% | -429.60% |
| Return on Equity (ROE) | 108.67% | -576.58% |
| Return on Capital Employed (ROCE) | -137.91% | -575.98% |
| Return on Invested Capital (ROIC) | -137.91% | -575.98% |
| Return on Tangible Assets | -288.71% | -429.60% |
| Earnings Yield | -0.67% | -0.07% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 0.07 | 0.22 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | -5110.00 | -1688.12 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 5110.00 | 1688.12 |
| Operating Cycle | 0.00 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -0.02 | -0.01 |
| Free Cash Flow Per Share | -0.02 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -89.25 | -124.69 |
| Capital Expenditure Coverage Ratio | -89.25 | -124.69 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.16% | -0.02% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -149.39 | -1448.07 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -162.34 | 8349.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -606.45 | -5521.83 |
| Price-to-Operating Cash Flow Ratio | -613.24 | -5566.12 |
| Price-to-Earnings Growth (PEG) Ratio | -1.24 | -44.57 |
| Enterprise Value Multiple | -429.02 | -1450.23 |
| Enterprise Value | 1.53B | 6.60B |
| EV to EBITDA | -429.02 | -1450.23 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | -605.07 | -5521.02 |
| EV to Operating Cash Flow | -611.85 | -5565.30 |
| Tangible Book Value Per Share | -0.06 | 0.01 |
| Shareholders’ Equity Per Share | -0.06 | 0.01 |
| Tax and Other Ratios | ||
| Effective Tax Rate | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -0.07 | -0.03 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 2.87 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.24 | 0.26 |
Currency in USD
